Advanced Hepatocellular Carcinoma

Oncology
18
Pipeline Programs
16
Companies
21
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
11
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
467%
Monoclonal Antibody
117%
Peptide
117%
+ 13 programs with unclassified modality

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
OctreotidePhase 3Peptide1 trial
Active Trials
NCT00241020Completed270Est. Oct 2005
E
EisaiChina - Liaoning
2 programs
1
1
LenvatinibPhase 2Small Molecule1 trial
H3B-6527Phase 11 trial
Active Trials
NCT02834780Completed128Est. Feb 2022
NCT03841201Completed50Est. May 2023
Taiho Oncology
Taiho OncologyNJ - Princeton
2 programs
2
TAC-101Phase 21 trial
TAC-101Phase 21 trial
Active Trials
NCT00667628TerminatedEst. Dec 2009
NCT00756782WithdrawnEst. Dec 2008
Abbott
AbbottABBOTT PARK, IL
1 program
1
ABT-869Phase 21 trial
Active Trials
NCT00517920Completed44Est. Jun 2012
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 386Phase 21 trial
Active Trials
NCT00872014Completed60Est. Jun 2015
One Biosciences
One BiosciencesFrance - Paris
1 program
1
ApatinibPhase 2Small Molecule1 trial
Active Trials
NCT01192971CompletedEst. Jul 2013
DS
Daiichi SankyoChina - Shanghai
1 program
1
CS-1008 2 mg/kgPhase 21 trial
Active Trials
NCT01033240Completed172Est. Sep 2013
Takeda
TakedaTOKYO, Japan
1 program
1
CabozantinibPhase 2Small Molecule4 trials
Active Trials
NCT05100082Completed263Est. Nov 2025
NCT04804813Completed388Est. Jul 2024
NCT04446117Active Not Recruiting575Est. Oct 2026
+1 more trials
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
Immuncell-LCPhase 21 trial
Active Trials
NCT01897610CompletedEst. Jul 2017
Bristol Myers Squibb
1 program
1
LenvatinibPhase 2Small Molecule
Akesobio
AkesobioChina - Zhongshan
1 program
1
LigufalimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06789848RecruitingEst. May 2030
CT
2 programs
2
Penpulimab injectionPhase 11 trial
TQB2223 injectionPhase 11 trial
Active Trials
NCT05975645TerminatedEst. Jun 2025
NCT06320080TerminatedEst. Nov 2025
Alnylam Pharmaceuticals
1 program
1
ALN-BCATPhase 11 trial
Active Trials
NCT06600321Recruiting158Est. Oct 2027
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
AU409Phase 11 trial
Active Trials
NCT06374485Recruiting18Est. Dec 2025
Highlight Therapeutics
Highlight TherapeuticsSpain - Valencia
1 program
1
Nanoplexed Poly I:C BO-112Phase 11 trial
Active Trials
NCT04777708Terminated1Est. Mar 2023
QT
Q TherapeuticsUT - Salt Lake City
1 program
Oligo FucoidanN/A1 trial
Active Trials
NCT04066660TerminatedEst. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
TakedaCabozantinib
NovartisOctreotide
AkesobioLigufalimab
EisaiLenvatinib
TakedaCabozantinib
GC BiopharmaImmuncell-LC
Daiichi SankyoCS-1008 2 mg/kg
One BiosciencesApatinib
AmgenAMG 386
Taiho OncologyTAC-101
Taiho OncologyTAC-101
AbbottABT-869
Alnylam PharmaceuticalsALN-BCAT
Chia Tai TianQing Pharmaceutical GroupTQB2223 injection
Lee's PharmaceuticalAU409

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 2,161 patients across 21 trials

NCT04446117TakedaCabozantinib

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Start: Oct 2020Est. completion: Oct 2026575 patients
Phase 3Active Not Recruiting
NCT00241020NovartisOctreotide

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

Start: Jun 2002Est. completion: Oct 2005270 patients
Phase 3Completed
NCT06789848AkesobioLigufalimab

Ligufalimab and Cadonilimab in Advanced Liver Cancers

Start: Feb 2025Est. completion: May 2030
Phase 2Recruiting
NCT03841201EisaiLenvatinib

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

Start: Jun 2019Est. completion: May 202350 patients
Phase 2Completed
NCT03586973TakedaCabozantinib

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

Start: Aug 2018Est. completion: Jun 202134 patients
Phase 2Completed
NCT01897610GC BiopharmaImmuncell-LC

Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC

Start: Dec 2013Est. completion: Jul 2017
Phase 2Completed
NCT01033240Daiichi SankyoCS-1008 2 mg/kg

CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

Start: Jul 2010Est. completion: Sep 2013172 patients
Phase 2Completed
NCT01192971One BiosciencesApatinib

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

Start: Jun 2010Est. completion: Jul 2013
Phase 2Completed
NCT00872014AmgenAMG 386

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Start: Aug 2009Est. completion: Jun 201560 patients
Phase 2Completed
NCT00756782Taiho OncologyTAC-101

A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma

Start: Oct 2008Est. completion: Dec 2008
Phase 2Withdrawn
NCT00667628Taiho OncologyTAC-101

Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma

Start: Apr 2008Est. completion: Dec 2009
Phase 2Terminated
NCT00517920AbbottABT-869

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Start: Sep 2007Est. completion: Jun 201244 patients
Phase 2Completed
NCT06600321Alnylam PharmaceuticalsALN-BCAT

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Start: Dec 2024Est. completion: Oct 2027158 patients
Phase 1Recruiting
NCT06320080Chia Tai TianQing Pharmaceutical GroupTQB2223 injection

Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.

Start: May 2024Est. completion: Nov 2025
Phase 1Terminated
NCT06374485Lee's PharmaceuticalAU409

Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment

Start: May 2024Est. completion: Dec 202518 patients
Phase 1Recruiting
NCT05975645Chia Tai TianQing Pharmaceutical GroupPenpulimab injection

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Start: Aug 2023Est. completion: Jun 2025
Phase 1Terminated
NCT04777708Highlight TherapeuticsNanoplexed Poly I:C BO-112

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Start: Oct 2021Est. completion: Mar 20231 patients
Phase 1Terminated
NCT02834780EisaiH3B-6527

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Start: Dec 2016Est. completion: Feb 2022128 patients
Phase 1Completed
NCT05100082TakedaCabozantinib

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Start: Nov 2021Est. completion: Nov 2025263 patients
N/ACompleted
NCT04804813TakedaCabozantinib

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Start: Mar 2021Est. completion: Jul 2024388 patients
N/ACompleted
NCT04066660Q TherapeuticsOligo Fucoidan

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Start: Oct 2019Est. completion: Jul 2024
N/ATerminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 2,161 patients
16 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)